Eisai China's Mecobalamin Tablets (Mikobal) Successfully Selected in the Third Round of National Centralized Drug Procurement

Shanghai, August 21, 2020 /PRNewswire/ -- On August 20, Eisai China participated in the third national centralized drug procurement organized by the Joint Procurement Office for National Centralized Drug Volume-Based Procurement and Use. Eisai China proactively reduced the price of Methycobal tablets (mecobalamin formulation), stood out from intense competition, and successfully won the bid.

Feng Yanhui, President of Eisai China, stated that upholding the “hhc("Caring for human health") As its corporate philosophy, Eisai China is committed to serving human healthcare and has always regarded fulfilling social responsibility as an important corporate mission. It is believed that with the selection of Methycobal tablets in the centralized procurement, more patients will benefit and clinical needs will be met.

Since entering the Chinese market in the early 1990s, Eisai China has achieved steady growth and development, establishing a business model with Eisai (China) Investment Co., Ltd. as the capital control and management entity, supported by Eisai (China) Pharmaceutical Co., Ltd., Eisai (Liaoning) Pharmaceutical Co., Ltd., and Eisai (Suzhou) Trading Co., Ltd. Currently, the total registered capital of Eisai China has reached 10,USD 8.54 million, with a development scale that has formed a focus on the fields of neuroscience, oncology (specialty drugs), and gastroenterology/hepatology, with dozens of pharmaceutical products being sold in China.

Regarding future development in the Chinese market, we aim to bring greater benefits to patients in China. Eisai China will continue to launch new products and new indications in the fields of central nervous system disorders and oncology. Meanwhile, Eisai China will actively expand its regional presence in the Chinese market. In addition to focusing on major cities and large hospitals as in the past, we strive to extend the reach of Eisai China’s products to smaller cities and hospitals, thereby making them accessible to more patients across China. By prioritizing the interests of patients and their families, we are committed to contributing to the enhancement of their well-being.